Soft Tissue Sarcoma Market: Growth Drivers, Emerging Therapies, and the Road to 2036

Soft Tissue Sarcoma Market: Growth Drivers, Emerging Therapies, and the Road to 2036

Soft tissue sarcoma (STS) is a rare group of cancers that develop in muscle, fat, nerves, blood vessels, and connective tissue. Its many subtypes behave very differently, from slow-growing local masses to aggressive metastatic disease. High recurrence risk and limited options in advanced stages have made it a persistent challenge for oncologists. That challenge is also drawing growing commercial and scientific attention.

According to DelveInsight's analysis, the Soft Tissue Sarcoma market across the 7MM (the US, EU4, the UK, and Japan) was worth roughly USD 310 million in 2025. It is projected to grow at a CAGR of about 7.9% between 2026 and 2036. This article draws on that Soft Tissue Sarcoma market research to look at where the market stands and where it is heading.

Soft Tissue Sarcoma Market Size and Regional Snapshot

The United States is the largest regional market. It generated about USD 270 million in 2025 and is expected to account for roughly 69% of the 7MM total by 2036. DelveInsight attributes this leadership to strong diagnostic awareness, advanced healthcare infrastructure, and high participation in clinical research.

The patient burden is significant. The 7MM recorded about 40,000 incident STS cases in 2025, and the number is expected to rise through 2036. The US alone exceeded 13,500 cases. Age matters: in the US, patients aged 65 and above made up the largest group (about 6,300 cases), followed by those aged 45–64 (about 4,000). Japan shows a similar pattern, with about 2,700 cases in the 65-and-above group. Germany's type-specific data shows how varied the disease is, with sarcoma NOS at about 1,500 cases and liposarcoma at about 1,050.

Key Soft Tissue Sarcoma Factors Driving Growth

Several forces underpin this Soft Tissue Sarcoma market insight:

• Rising incidence and disease burden. Better diagnostics, aging populations, and longer survival all enlarge the patient pool that needs treatment.

• Diagnostic advances. Improvements in MRI and CT imaging, biopsy techniques, and molecular testing allow earlier, more accurate identification and subtyping.

• Stronger R&D activity. Pharmaceutical and biotech companies are investing in new agents, targeted treatments, and immunotherapies for a historically underserved indication.

• Targeted therapy and immunotherapy. Treatments aimed at specific molecular pathways or at boosting the immune response are changing what is clinically possible.

• Awareness and personalized medicine. Advocacy and education encourage earlier care, while biomarker-based approaches help match patients to the therapies most likely to work.

Soft Tissue Sarcoma Current Treatment Landscape

Care for STS is multidisciplinary. Surgery remains the primary option for localized disease and is often paired with radiation to reduce recurrence. Chemotherapy is common in high-grade, advanced, or metastatic cases, and tyrosine kinase inhibitors and immunotherapies are gradually widening the options for selected subtypes.

Three approved therapies stand out in the analysis:

1. Trabectedin (YONDELIS) from Pharma Mar and Janssen. This DNA-binding agent is approved for advanced STS after anthracycline-based treatment, including liposarcoma and leiomyosarcoma in the US. It remains one of the few second-line options for these histologies.

2. Afami-cel (TECELRA) from US WorldMeds. It received FDA accelerated approval in August 2024 for unresectable or metastatic synovial sarcoma and is the first approved TCR T-cell therapy in oncology. It is directed at MAGE-A4-positive tumors, and the Phase II SPEARHEAD-1 trial reported an objective response rate of roughly 39%.

3. Atezolizumab (TECENTRIQ / TECENTRIQ HYBREZA) from Roche/Genentech. This PD-L1 inhibitor is approved for alveolar soft part sarcoma. Its subcutaneous version was the first PD-(L)1 immunotherapy cleared for subcutaneous use in the EU.

Soft Tissue Sarcoma Emerging Pipeline: What Comes Next

The pipeline points toward cell therapy, intratumoral delivery, and novel cytotoxics:

• TBI-1301 (mipetresgene autoleucel), Takara Bio. This TCR gene therapy targets NY-ESO-1-positive tumors and is in a Phase III confirmatory trial for advanced synovial sarcoma. It received Rare Disease and Sakigake designations in Japan in 2025.

• INT230-6, Intensity Therapeutics. This intratumoral combination of cisplatin and vinblastine is in the Phase III INVINCIBLE-3 trial. Enrollment was temporarily paused in early 2026 for funding reasons, after 21 patients had been enrolled.

• Lurbinectedin (ZEPZELCA), Pharma Mar/Jazz. Enrollment in the Phase III SaLuDo trial, testing it with doxorubicin as first-line treatment for metastatic leiomyosarcoma, was completed in May 2026. A US launch in this indication is anticipated around 2028.

Other candidates include catequentinib (already approved in China for advanced STS), abemaciclib, and combination immunotherapy approaches from companies such as Replimune and Immutep. The number of agents in development reflects real momentum, though many face the usual hurdles of small trial populations and heterogeneous disease.

Soft Tissue Sarcoma Market Unmet Needs and Market Challenges

Despite progress, the gaps are substantial. DelveInsight highlights the lack of durable disease control in advanced STS, the fragmented biology that makes it hard to apply findings across subtypes, the rapid development of resistance across lines of therapy, and a plateau in later-line efficacy. Existing systemic therapies often deliver modest survival benefit alongside considerable toxicity.

Expert commentary in the report reinforces this. Clinicians stress that outcomes depend on expert-led multidisciplinary care, that delayed or incorrect diagnoses remain a problem before patients reach specialist centers, and that molecular characterization is pushing the field toward histology-specific, biomarker-guided treatment.

Access and pricing add another layer. Advanced therapies such as cell therapies carry high costs, so reimbursement decisions and market access will shape how quickly new options reach patients.

Soft Tissue Sarcoma Market Trends to Watch

Several Soft Tissue Sarcoma market trends are likely to define the coming decade:

• A shift from broad cytotoxics to precision oncology, with treatment selected by subtype and biomarker.

• Engineered cell therapies moving into solid tumors, with TECELRA as a proof of concept and TBI-1301 following.

• Immunotherapy expansion, including new formulations and combination regimens.

• Novel delivery approaches, such as intratumoral injection, aimed at improving efficacy and tolerability.

• Continued US dominance, alongside gradual growth in EU4, the UK, and Japan.

Soft Tissue Sarcoma Market Outlook

The STS market is at an inflection point. It was long dominated by surgery, radiation, and conventional chemotherapy, and it is now being reshaped by targeted agents, immunotherapies, and engineered cell therapies. With a projected 7.9% CAGR through 2036, a growing patient population, and a pipeline of late-stage candidates, the sector offers meaningful opportunities for developers, investors, and healthcare stakeholders. It also carries real scientific and commercial risk, as the INT230-6 funding pause shows. For patients, the hope is a move from limited, short-lived options toward durable, subtype-specific treatment.

Delveinsight Related Reports
progeria, nanobots, medical device distributors spain surgical navigation systems, benjamin button disease, treatment molluscum, mcrpc, robotics in healthcare, cgrp inhibitors, progeria syndrome, benjamin button disorder, liver cirrhosis clinical trial 2026 update press release, spain distributors surgical navigation systems neurosurgery, ulcerative colitis meds, ptcl, progeria disease,